Nxera Pharma Co.,Ltd. (4565.T) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	34.2B	29.6B	28.8B	12.8B	15.6B
Cost of Revenue	—	8.2B	7.6B	3.1B	926.0M
Gross Profit	—	21.4B	21.2B	9.7B	14.6B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	—	15.2B	16.0B	10.0B	4.4B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	1.8B	100.0M	94.0M	2.0M
Total Operating Expenses	—	17.1B	16.1B	10.1B	4.4B
Cost and Expenses	37.3B	38.1B	34.3B	22.3B	12.1B
Operating Income (EBIT)	(3.0B)	(8.5B)	(5.4B)	(9.5B)	3.4B
Non-Operating
Interest Income	—	987.0M	1.5B	1.3B	663.0M
Interest Expense	—	7.5B	783.0M	2.5B	756.0M
Net Interest Income	—	(6.5B)	761.0M	(1.2B)	(93.0M)
Other Non-Op Income/Expense	—	1.7B	1.3B	944.0M	626.0M
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	(1.6B)	(14.9B)	(4.7B)	(10.7B)	1.1B
Income Tax Expense	—	(2.4B)	176.0M	(3.5B)	696.0M
Bottom Line
Net Income	(10.0B)	(12.5B)	(4.8B)	(7.2B)	382.0M
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(12.4B)	(12.5B)	(4.8B)	(7.2B)	382.0M
Per Share
Basic EPS	(¥111)	(¥139)	(¥54)	(¥87)	¥5
Diluted EPS	(¥111)	(¥139)	(¥54)	(¥87)	¥5
Revenue Per Share	¥378	¥328	¥321	¥155	¥190
Shares
Basic Shares Outstanding	90.5M	90.3M	89.7M	82.5M	81.8M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	3.4B	(4.1B)	(1.4B)	(7.0B)	4.8B
D&A	3.3B	4.4B	4.0B	2.5B	1.3B
EBIT	(3.0B)	(8.5B)	(5.4B)	(9.5B)	3.4B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026